NeuroPace, Inc.
NASDAQ:NPCEMedical - Devices
+$0.05 today
- Market cap
- $280.44M
- Beta
- 1.88
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.64
Volume 0.35M
Average 0.18M
Returns on capital
NeuroPace, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-112.8%
avg -108.0%
ROIC
-18.2%
avg -58.7%
ROA
-20.3%
avg -47.6%
Analysis
ROIC is currently the strongest return metric at -18.2% versus its period average of -58.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joel D. Becker | Chief Executive Officer, President & Director | USD 1.12M | 58 | — | — |
Martha J. Morrell | Chief Medical Officer | USD 725.32K | 69 | — | — |
Patrick F. Williams | Chief Financial Officer | USD 689.41K | 53 | 67.51K | 0.20% |
Chris Reese | Senior Vice President of Sales | — | — | — | — |
Dylan John | Chief of Operations & Development | — | — | — | — |
Scott R. Schaper | Head of Investor Relations | — | — | — | — |
Amy Treadwell | Vice President of Human Resources | — | — | — | — |
Julie Hsu | Vice President & Controller | — | — | — | — |
Katie Keller | Vice President of Marketing | — | — | — | — |
Leah Akin | General Counsel & Corporate Secretary | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$399,250.00
Net Transaction Value
−$399,250.00
Net selling
Most Active
Morrell Martha
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 15, 25Dec 15, 2025 | Morrell Martha Direct | Sell | $399.3K$399,250.00 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $399,250.00 over the last 12 months. That adds up to net selling of $399,250.00. Morrell Martha was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +30.0% | +14.7% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +30.0% over three years. Forward estimates point to Revenue at +14.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does NeuroPace, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NPCE's management, answered from reported figures.
Who manages NPCE?
NeuroPace, Inc. (NPCE) lists 10 active executives. The top listed executive is Chris Reese, Senior Vice President of Sales.
Are NPCE insiders buying or selling?
Recent insider activity shows net selling of $55.13M.
Continue the stock analysis
Jump to another research area for this company.